Tiziana Life Sciences Ltd (TLSA)

Market Cap	89.44M
Revenue (ttm)	n/a
Net Income (ttm)	-13.73M
Shares Out	109.09M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	480,667
Open	0.900
Previous Close	0.900
Day's Range	0.810 - 0.905
52-Week Range	0.410 - 1.740
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 4, 2025

About TLSA

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule bro...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 24, 2000
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: TLSA
• Website: https://www.tizianalifesciences.com